
## **Christopher Finan**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3984968/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mendelian randomization of blood lipids for coronary heart disease. European Heart Journal, 2015, 36, 539-550.	1.0	567
2	Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ, The, 2014, 349, g4164-g4164.	3.0	528
3	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature Communications, 2020, 11, 163.	5.8	466
4	The druggable genome and support for target identification and validation in drug development. Science Translational Medicine, 2017, 9, .	5.8	437
5	Genetic drug target validation using Mendelian randomisation. Nature Communications, 2020, 11, 3255.	5.8	175
6	GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes. Nature Communications, 2018, 9, 5141.	5.8	119
7	Improving the odds of drug development success through human genomics: modelling study. Scientific Reports, 2019, 9, 18911.	1.6	112
8	Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Research, 2021, 6, 16.	0.9	90
9	Genetic architecture of host proteins involved in SARS-CoV-2 infection. Nature Communications, 2020, 11, 6397.	5.8	71
10	Lipid lowering and Alzheimer disease risk: A mendelian randomization study. Annals of Neurology, 2020, 87, 30-39.	2.8	64
11	Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nature Communications, 2021, 12, 5640.	5.8	57
12	Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization. Circulation, 2022, 145, 1205-1217.	1.6	50
13	Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Research, 2021, 6, 16.	0.9	48
14	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	5.8	44
15	Population Genomics of Cardiometabolic Traits: Design of the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium. PLoS ONE, 2013, 8, e71345.	1.1	39
16	Uncovering genetic mechanisms of hypertension through multi-omic analysis of the kidney. Nature Genetics, 2021, 53, 630-637.	9.4	37
17	Polygenic risk scores for coronary artery disease and subsequent event risk amongst established cases. Human Molecular Genetics, 2020, 29, 1388-1395.	1.4	23
18	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovascular Disorders, 2019, 19, 240.	0.7	22

#	Article	IF	CITATIONS
19	Obesity causes cardiovascular diseases: adding to the weight of evidence. European Heart Journal, 2020, 41, 227-230.	1.0	16
20	Human Genomics and Drug Development. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a039230.	2.9	16
21	Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics. Nature Communications, 2021, 12, 6120.	5.8	13